Patient Services Vie For Bigger Share Of AIDS Funds

WASHINGTON-In the early 1980s, the lonely voices seeking funds for AIDS research were barely audible amid the din from the biomedical community as a whole. Over the past eight years, however, with the public also demanding that science step up its battle against the devastating-disease, the United States government has poured $5.5 billion into the AIDS epidemic, including $2.1 billion in the current year ending September 30. So far, about 40% of that total, nearly $2.2 billion, has been spent on

Written byElizabeth Pennisi
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

However, while the investment in basic research has added greatly to the store of knowledge about the AIDS virus, it has not yet led to an effective treatment: much less a cure. At the same time, more people are getting sick and living longer with the disease. And their plight threatens to control the hearts and. purse strings of society and drown out those who advocate the cause of science.

"AIDS is now a treatable disease," says Reed V. Tuckson, District of Columbia commissioner of health. "The implications of that are tremendous. Few health care systems are equipped to handle what's coming; nor is there much planning going on." Given the nation's limited resources, he adds, efforts to cope with the problem are "going to make Americans look like barbarians."

For scientists, the overwhelming need for care forebodes a potential squeeze on scarce resources. "We have a national consensus on ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies